CMS has announced it will cover a maximum of three scans using 18F-FDG-PET for oncology treatment planning. The final decision is a modification of the agency's previous proposal, which covered only one FDG-PET scan and excluded prostate cancer as an indication for coverage. The decision also applies to all Medicare beneficiaries, as opposed to the previous proposal that left coverage determinations up to local Medicare contractors, and removes the need for prospective data collection by the National Oncologic PET Registry for cancer coverage. SNMMI has lauded the decision, saying it "will have a significant impact on patient care."

Related Summaries